Aim - to compare cancer-specific survival rates for familial and sporadic prostate cancer patients. Gleason score and age at diagnosis of familial group and sporadic group were compared by <$Echi sup 2> and t-test. Cancer-specific survival rates were analyzed by tbe Kaplan - Meier method and compared by log-rank test. Statistically significant level was set at p << 0,05. Among 1175 prostate cancer patients, familial group consisted of 215 (18,3 %) patients, tbe sporadic group consisted of 960 (81,7 %) patients. The familial group patient's mean age at diagnosis (58,9 years old, 95 % confidence interval (CI) 57,8 - 60,1) was significantly younger than that of sporadic group patients (67,2 years old, 95 % CI 66,7 - 67,6) (p << 0,0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92 % (95 % CI 0,88 - 0,97) of familial group patients had a 10-year cancerspecific survival rates, which was a significantly better outcome than that of sporadic group with 69 % (95 % CI 0,60 - 0,78) 10-year cancer-specific survival rates (p = 0,0237). Conclusion: the study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancerspecific survival rates, but not Gleason score.